Fludarabine
Metastases, Neoplasm
Jonsson Comprehensive Cancer CenterSmall moleculePhase 1/2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 95/ 100
Competitive context
171 Active assets in the Metastases, Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Ruijin Hospital | Phase 4 | BBB |
FLUOROURACILUM Ruijin Hospital | Phase 4 | BBB |
Irinotecan Eli Lilly and Company | Phase 4 | BBB |
DEXAMETHASONE Janssen Research & Development, LLC | Phase 2 | BBB |
Ipilimumab 7 Hills Pharma, LLC | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →